RxDoctor Payments Data

Christopher Randolph, MD

Psychiatry · Roanoke, ALNPI 1669455606

Payments from drug & device makers

$4,152in general payments, 2019–2025

Across 231 payments — averaging $17.98 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • Teva Pharmaceuticals USA, Inc.$451
  • Otsuka America Pharmaceutical, Inc.$389
  • Alkermes, Inc.$357
  • Neurocrine Biosciences, Inc.$334
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$280
  • plus $1K from 14 others

What the payments were for

  • Food & beverage$3,79491%
  • Education$3589%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$4,152 in reported general payments places this provider in the 80th percentile of 400 psychiatry providers in Alabama.

See all psychiatry providers in Alabama

Medicare billing

Part B allowed, 2024
$52,709
Medicare patients
150
Services billed
578

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Austedo XrDeutetrabenazine32$237,133
AustedoDeutetrabenazine11$72,921
RexultiBrexpiprazole28$45,871
CaplytaLumateperone Tosylate15$30,780
Lurasidone Hcl149$29,914
TrintellixVortioxetine Hydrobromide32$21,530
NuedextaDextromethorphan Hbr/Quinidine12$18,162
Duloxetine Hcl363$6,891
Aripiprazole124$6,168
Dextroamphetamine-Amphet ErDextroamphetamine/Amphetamine65$5,205
Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl46$5,180
Buspirone Hcl392$4,784
VyvanseLisdexamfetamine Dimesylate12$4,378
Quetiapine Fumarate312$3,979
Divalproex Sodium ErDivalproex Sodium33$3,436

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Teva Pharmaceuticals USA, Inc.Austedo Xr, Austedo$451$310,05443 claims
Otsuka America Pharmaceutical, Inc.Rexulti$389$45,87128 claims
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta$280$30,78015 claims
Takeda Pharmaceuticals U.S.A., Inc.Trintellix, Vyvanse$254$25,90844 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 400 psychiatry providers in Alabama.

Other psychiatry in Roanoke

See the full list for Alabama

Where these figures come from

Is this you, or does something look wrong? →